Emergent BioSolutions | EBS - Trade Creditors


Emergent BioSolutions reported $112.2M in Trade Creditors for its fiscal quarter ending in December of 2023.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Akebia Therapeutics USD 7.61M 1.81M Sep/2026
ALKERMES USD 107.69M 35.17M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amarin USD 40.43M 21.63M Sep/2026
ANI Pharmaceuticals USD 74.41M 585K Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Coherus Biosciences USD 13.17M 1.69M Jun/2026
Emergent BioSolutions USD 112.2M 500K Dec/2023
Exelixis USD 30.83M 8.23M Sep/2026
Glaxosmithkline GBP 15.63B 1.3B Sep/2026
Heron Therapeutics USD 8.38M 3.27M Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
Ironwood Pharmaceuticals USD 3.62M 2.7M Sep/2026
Lexicon Pharmaceuticals USD 3M 87K Mar/2026
Lonza CHF 471M 3M Dec/2024
Merck USD 5.03B 1.2B Sep/2026
Moderna USD 259M 92M Sep/2026
Myriad Genetics USD 30.4M 2.2M Jun/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Pacira USD 17.5M 4K Sep/2026
Pfizer USD 4.07B 511M Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Sanofi EUR 24.55B 957M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
United Therapeutics USD 520.2M 22.4M Sep/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024